The short version of pentapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-17. Anything still debated is marked as such rather than presented as settled.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
In June the company announced it would acquire startup Emergence Therapeutics for an undisclosed sum and Sigilon Therapeutics for $300 million. The company's 2023 research and development focus has been reported to be on drugs in the obesity, diabetes, Alzheimer's and autoimmune areas. In March 2023, Eli Lilly announced a $35 cap on the price of monthly insulin to be put in place immediately in order to be in line with the Inflation Reduction Act. In July 2023, Lilly announced it would acquire Versanis for $1.93 billion. In October 2023, Eli Lilly acquired Point Biopharma for $1.4 billion. In November 2023, the FDA approved tirzepatide for the treatment of obesity under the brand name Zepbound. In 2024, the FDA and the UK approved Donanemab, sold under the brand name Kisunla, a monoclonal antibody used for the treatment of Alzheimer's disease. In January 2026, Eli Lilly agreed to buy Ventyx Biosciences for $1.2 billion. The transaction was expected to close in 1H 2026. In March 2026, Eli Lilly announced a drug discovery deal with InSilico for an estimated value of $2.75 billion. In July 2026, Eli Lilly entered into an agreement to acquire AtaiBeckley in 2026.
== Distribution == The royal angelfish is widely distributed throughout the Indo-Pacific. The species can be found in the Red Sea and Indian Ocean around East Africa and the Maldives, stretching to the Tuamoto Islands, New Caledonia, and Great Barrier Reef. The northernmost limits of its range ends in the southern East China Sea around Taiwan and the Ryukyu Islands and Ogasawara Islands of Japan.
The growing season lasts approximately 135 days, from early in May until late in September, but agriculture is limited to the raising of few vegetables. With the exception of some stunted willows, the vast majority of the chain is devoid of native trees. On some of the islands, such as Adak and Amaknak, there are a few coniferous trees growing, remnants of the Russian period. While tall trees grow in many cold climates, Aleutian conifers — some estimated to be two hundred years old — rarely reach a height of even 10 feet (3 m), and many of them are still less than 5 feet (1.5 m) tall. This is because the islands, much like the Falklands and other islands of similar latitudes, experience such strong winds that taller trees are vulnerable to snapping off. Instead of trees, the islands are covered with a luxuriant, dense growth of herbage and shrubs, including crowberry, bluejoint, grasses, sedges, and many flowering plants. There are areas of peat bog near the coasts. Endemic plants include the endangered Aleutian shield fern. There is currently almost no naturally occurring forest in the Aleutian Islands, except with the help of human intervention. For example, the “Adak National Forest” on Adak Island is a man-made tree group consisting of 33 trees.
USA Defence Secretary Donald Rumsfeld told an armed services committee of the Senate on 2004-05-07 that "There are a lot more photographs and videos that exist [...] I looked at them last night and they're hard to believe [...] The pictures I've seen depict conduct, behaviour that is so brutal and so cruel and so inhumane that anyone engaged in it or involved in it would have to be brought to justice." He also said that the abused detainees may be offered compensation. In a scene described as "surreal" by AFP, it was found in mid May, 2004 that US troops were handing out cash to freed prisoners along with a note stating "You have not been mistreated.". A reporter visiting the prison Camp War Horse described the tour:
The mdx mouse has been at the forefront of CRISPR-Cas9 gene editing research for Duchenne muscular dystrophy. In 2014, the first successful correction of the dystrophin mutation using CRISPR-Cas9 was demonstrated directly in mdx mice, marking a historic milestone in gene editing therapy. In 2018, researchers used AAV-delivered CRISPR-Cas9 to restore dystrophin expression in mdx mice following a single systemic injection, demonstrating the remarkable potential of this approach. These results in mdx mice directly led to the first CRISPR-based clinical trials for DMD in human patients, representing a direct translation from mouse model to human medicine.
Sources: en.wikipedia.org
Half-Life: Opposing Force is an expansion pack for the first-person shooter game Half-Life (1998). It was developed by Gearbox Software and published by Sierra On-Line for Windows on November 19, 1999. Opposing Force was the first expansion for Half-Life and was announced in April 1999. Lead designer Randy Pitchford believed Gearbox was selected to develop Opposing Force because Valve, the creators of Half-Life, wanted to concentrate on their future projects. Over the course of development, Gearbox brought in a variety of talent from other areas of the video games industry to help bolster various aspects of design. Opposing Force portrays the events of Half-Life from the perspective of a U.S. Marine, one of the enemy characters in the original, assigned to the Hazardous Environment Combat Unit (HECU). The player character, Adrian Shephard, is sent in to neutralize the Black Mesa Research Facility when a scientific mishap causes it to be invaded by aliens, but quickly finds that the Marines are outnumbered and slowly being beaten back by a second alien race and black operations units. Opposing Force was received well by critics, with many describing it as the new benchmark title for expansion packs, in a similar fashion to how Half-Life revolutionized the first-person shooter genre. Other reviewers, however, thought that, despite its accomplishments, it still suffered from the negative aspects of other expansion packs.
== Classes == Different hormones can be sorted into different classes, depending on their chemical structures. Within each class of hormone, chemical structures can vary, but all members of the same class have similar physiological effects. Initial research into plant hormones identified five major classes: abscisic acid, auxins, gibberellins, cytokinins and ethylene. This list was later expanded, and brassinosteroids, jasmonates, salicylic acid, and strigolactones are now also considered major plant hormones. Additionally there are several other compounds that serve functions similar to the major hormones, but their status as bona fide hormones is still debated.
It was a pragmatic system based on the primacy of the strong – a "trusteeship of the powerful", as he then called it, or, as he put it later, "the Four Policemen". The concept was, as [Senator Arthur H.] Vandenberg noted in his diary in April 1944, "anything but a wild-eyed internationalist dream of a world state. ... It is based virtually on a four-power alliance." Eventually this proved to be both the potential strength and the actual weakness of the future UN, an organization theoretically based on a concert of great powers whose own mutual hostility, as it turned out, was itself the greatest potential threat to world peace.
The underconnectivity theory of autism posits that autistic people tend to have fewer high-level neural connections and less global synchronization, along with an excess of low-level processes. Functional connectivity studies have found both hypo- and hyperconnectivity in brains of autistic people. Hypoconnectivity is commonly observed for interhemispheric (e.g. lower neuron density in corpus callosum) and cortico-cortical functional connectivity. Some studies have found local overconnectivity in the cerebral cortex and weak functional connections between the frontal lobe and the rest of the cortex. Abnormal default mode network (task-negative) connectivity is often observed. Toggling between task-negative network activation and task-positive network activation (consisting of the dorsal attention network and salience network) may be less efficient, possibly reflecting a disturbance of self-referential thought. Such patterns of low function and aberrant activation in the brain may depend on whether the brain is performing social or nonsocial tasks. Some studies have suggested that autism is a disorder of the association cortex. Event-related potentials with respect to attention, orientation to auditory and visual stimuli, novelty detection, language and face processing, and information storage are altered in autistic individuals; several studies have found a preference for nonsocial stimuli. Magnetoencephalography studies have observed delayed processing of auditory signals in autistic children.
== Dipole moment == A helix has an overall dipole moment due to the aggregate effect of the individual microdipoles from the carbonyl groups of the peptide bond pointing along the helix axis. The effects of this macrodipole are a matter of some controversy. α-helices often occur with the N-terminal end bound by a negatively charged group, sometimes an amino acid side chain such as glutamate or aspartate, or sometimes a phosphate ion. Some regard the helix macrodipole as interacting electrostatically with such groups. Others feel that this is misleading and it is more realistic to say that the hydrogen bond potential of the free NH groups at the N-terminus of an α-helix can be satisfied by hydrogen bonding; this can also be regarded as set of interactions between local microdipoles such as C=O···H−N.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.